

Press Release

Nextech Invest Names Thomas Lips Partner

Former CEO of Centrum Bank strengthens Nextech Invest's global growth initiative

Zurich (Switzerland), March 24, 2014 – Nextech Invest Ltd. announced today that Thomas Lips was assigned as the company's new partner. In his novel role, Lips will be responsible to strengthen Nextech's global growth in private equity investments in leading cancer companies.

Dr. Thomas Lips has over 30 years of experience in the asset management and financial services industry. Over the last two years, Lips served as Chief Executive Officer at Centrum Bank, Liechtenstein. Prior to that, he held the position of Chief Investment Officer and Head of Asset Management at Falcon Private Bank (formerly AIG Private Bank) between 1998 and January 2010. From 1993 until 1998 he was Chief Investment Officer at Goldman Sachs & Co. Bank in Switzerland. He started his career in 1981 at the Union Bank of Switzerland (now UBS), where he was responsible for investment advisory and financial analysis activities and chaired the Investment Committee. Lips serves on boards of several companies in the financial services industry among others as chairman of Ayaltis, a Swiss-based fund of hedge funds, as president of the board of directors at the Swiss Training Centre for Investment Professionals (AZEK) and as board member of the Executive Committee of the Swiss Financial Analysts Association (SFAA). Lips earned his Doctorate in Economics from the University of Zurich in 1981.

"We are very fortunate that Thomas Lips has joined our team," said Alfred Scheidegger, Founder and CEO of Nextech Invest. "With his experience in the asset management and financial services industry, Lips is a valuable addition to Nextech's team, as part of our global growth initiative."

"Nextech has built a longstanding expertise in private equity investments in cancer companies, the fastest growing field in healthcare. Through its exclusive 7-member Scientific Advisory Board, Nextech understands the industry very well and I look forward to be part of this ambitious team," commented Thomas Lips.

About Nextech Invest Ltd.

The global specialist life sciences venture capital firm Nextech Invest Ltd., established in 1998, focuses on investing in oncology related companies. Supported by an outstanding Scientific Advisory Board of seven world-leading oncologists chaired by Professor David Livingston, Deputy Director Dana-Farber/Harvard Cancer Center, Nextech Invest is investing in emerging companies with pioneering innovations in cancer research that have compounds in advanced clinical trials. The two Nextech funds have a total of US\$ 100 million under management. Nextech Invest has made ten investments to date, of which three have already been exited. Nextech Invest, based in Zurich, is a longstanding member of leading networks in private equity, such as EVCA, SECA and EVPA. Nextech Invest works closely with the Union for International

Cancer Control (UICC).

For more information, please contact:

Alfred Scheidegger

PhD, Founding Partner & CEO

Nextech Invest Ltd.

Tel.: +41 44 366 66 12

scheidegger@nextechinvest.com

www.nextechinvest.com